(Q56172239)

1

object named as

Julie K. Heimbach

0 references

author name string

Laura M. Kulik

2

0 references

Richard S. Finn

3

0 references

Claude B. Sirlin

4

0 references

Michael M. Abecassis

5

0 references

Andrew X. Zhu

7

0 references

M. Hassan Murad

8

0 references

Jorge A. Marrero

Grading quality of evidence and strength of recommendations

9

0 references

language of work or name

English

0 references

publication date

19 December 2017

0 references

published in

Hepatology

0 references

volume

67

0 references

issue

1

0 references

page(s)

358-380

0 references

cites work

1 reference

Management of hepatocellular carcinoma: An update

21 January 2018

1 reference

Comparison of hepatocellular carcinoma in Eastern versus Western populations.

21 January 2018

1 reference

International trends in liver cancer incidence, overall and by histologic subtype, 1978-2007.

21 January 2018

1 reference

Future of Hepatocellular Carcinoma Incidence in the United States Forecast Through 2030

21 January 2018

1 reference

Population attributable fractions of risk factors for hepatocellular carcinoma in the United States.

21 January 2018

1 reference

Hepatocellular carcinoma in cirrhosis: incidence and risk factors

21 January 2018

1 reference

Increasing prevalence of HCC and cirrhosis in patients with chronic hepatitis C virus infection

21 January 2018

1 reference

21 January 2018

Hepatocellular carcinoma

1 reference

Randomized controlled trial of screening for hepatocellular carcinoma

21 January 2018

1 reference

Early detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with cirrhosis: a meta-analysis

21 January 2018

1 reference

Update on biomarkers of hepatocellular carcinoma

21 January 2018

1 reference

Nephrogenic systemic fibrosis: history and epidemiology

21 January 2018

1 reference

Contrast-induced nephropathy in CT: incidence, risk factors and strategies for prevention

21 January 2018

1 reference

Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma.

21 January 2018

1 reference

Small nodules (1-2 cm) in liver cirrhosis: characterization with contrast-enhanced ultrasound

21 January 2018

1 reference

The impact of vascular and nonvascular findings on the noninvasive diagnosis of small hepatocellular carcinoma based on the EASL and AASLD criteria

21 January 2018

1 reference

Characterization of primary and recurrent nodules in liver cirrhosis using contrast-enhanced ultrasound: which vascular criteria should be adopted?

21 January 2018

1 reference

Clinical and economical impact of 2010 AASLD guidelines for the diagnosis of hepatocellular carcinoma.

21 January 2018

1 reference

Contrast-enhanced ultrasound assessment of arterial vascularization of small nodules arising in the cirrhotic liver.

21 January 2018

1 reference

The diagnostic and economic impact of contrast imaging techniques in the diagnosis of small hepatocellular carcinoma in cirrhosis

21 January 2018

1 reference

Contrast-enhanced ultrasound for the differentiation of small atypical hepatocellular carcinomas from dysplastic nodules in cirrhosis

21 January 2018

1 reference

Seeding following percutaneous diagnostic and therapeutic approaches for hepatocellular carcinoma. What is the risk and the outcome? Seeding risk for percutaneous approach of HCC.

21 January 2018

1 reference

Indeterminate 1-2-cm nodules found on hepatocellular carcinoma surveillance: biopsy for all, some, or none?

21 January 2018

1 reference

Importance of small (< or = 20-mm) enhancing lesions seen only during the hepatic arterial phase at MR imaging of the cirrhotic liver: evaluation and comparison with whole explanted liver.

21 January 2018

1 reference

Outcome of small (10-20 mm) arterial phase-enhancing nodules seen on triphasic liver CT in patients with cirrhosis or chronic liver disease.

21 January 2018

1 reference

Clinical implication of small (<20 mm) enhancing hepatic nodules observed only during three-dimensional gadobenate dimeglumine-enhanced hepatic arterial-phase MRI of the hepatitis B virus-induced mild cirrhosis

21 January 2018

1 reference

Value of delayed hypointensity and delayed enhancing rim in magnetic resonance imaging diagnosis of small hepatocellular carcinoma in the cirrhotic liver

21 January 2018

1 reference

Analysis of gadobenate dimeglumine-enhanced MR findings for characterizing small (1-2-cm) hepatic nodules in patients at high risk for hepatocellular carcinoma.

21 January 2018

1 reference

Imaging Outcomes of Liver Imaging Reporting and Data System Version 2014 Category 2, 3, and 4 Observations Detected at CT and MR Imaging

21 January 2018

1 reference

Liver Imaging Reporting and Data System with MR Imaging: Evaluation in Nodules 20 mm or Smaller Detected in Cirrhosis at Screening US.

21 January 2018

1 reference

Accuracy and disagreement of computed tomography and magnetic resonance imaging for the diagnosis of small hepatocellular carcinoma and dysplastic nodules: role of biopsy.

21 January 2018

1 reference

A Randomized Trial Comparing Radiofrequency Ablation and Surgical Resection for HCC Conforming to the Milan Criteria

21 January 2018

1 reference

A randomized controlled trial of radiofrequency ablation and surgical resection in the treatment of small hepatocellular carcinoma.

21 January 2018

1 reference

A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma

21 January 2018

1 reference

Randomized clinical trial of chemoembolization plus radiofrequency ablation versus partial hepatectomy for hepatocellular carcinoma within the Milan criteria

21 January 2018

1 reference

Long-term effectiveness of resection and radiofrequency ablation for single hepatocellular carcinoma ≤3 cm. Results of a multicenter Italian survey

21 January 2018

1 reference

Prognostic Relevance of Objective Response According to EASL Criteria and mRECIST Criteria in Hepatocellular Carcinoma Patients Treated with Loco-Regional Therapies: A Literature-Based Meta-Analysis.

21 January 2018

1 reference

Peretinoin after curative therapy of hepatitis C-related hepatocellular carcinoma: a randomized double-blind placebo-controlled study

21 January 2018

1 reference

Sorafenib in advanced hepatocellular carcinoma

21 January 2018

1 reference

Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

A meta-analysis of adjuvant therapy after potentially curative treatment for hepatocellular carcinoma

21 January 2018

1 reference

Effect and safety of interferon for hepatocellular carcinoma: a systematic review and meta-analysis

21 January 2018

1 reference

Current systemic treatment of hepatocellular carcinoma: A review of the literature

21 January 2018

1 reference

Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals

21 January 2018

1 reference

Statin and the risk of hepatocellular carcinoma and death in a hospital-based hepatitis B-infected population: A propensity score landmark analysis.

21 January 2018

1 reference

Validation of the HCC-MELD for dropout probability in patients with small hepatocellular carcinoma undergoing locoregional therapy.

21 January 2018

1 reference

Intention to treat outcome of T1 hepatocellular carcinoma with the "wait and not ablate" approach until meeting T2 criteria for liver transplant listing

21 January 2018

1 reference

Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis

21 January 2018

1 reference

A follow-up analysis of the pattern and predictors of dropout from the waiting list for liver transplantation in patients with hepatocellular carcinoma: implications for the current organ allocation policy

21 January 2018

1 reference

Risk factors for liver transplant waitlist dropout in patients with hepatocellular carcinoma

21 January 2018

1 reference

Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report

21 January 2018

1 reference

The place of downstaging for hepatocellular carcinoma

21 January 2018

1 reference

Bridging locoregional therapy for hepatocellular carcinoma prior to liver transplantation

21 January 2018

1 reference

Tumor biology and pre-transplant locoregional treatments determine outcomes in patients with T3 hepatocellular carcinoma undergoing liver transplantation

21 January 2018

1 reference

Downstaging hepatocellular carcinoma: A systematic review and pooled analysis

21 January 2018

1 reference

Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival

21 January 2018

1 reference

Evaluation of transcatheter arterial embolization prior to percutaneous tumor ablation in patients with hepatocellular carcinoma: a randomized controlled trial

21 January 2018

1 reference

Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution.

21 January 2018

1 reference

Multicentre randomised phase III trial comparing Tamoxifen alone or with Transarterial Lipiodol Chemoembolisation for unresectable hepatocellular carcinoma in cirrhotic patients (Fédération Francophone de Cancérologie Digestive 9402).

21 January 2018

1 reference

Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma

21 January 2018

1 reference

Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial

21 January 2018

1 reference

Transarterial chemoembolization: Evidences from the literature and applications in hepatocellular carcinoma patients

21 January 2018

1 reference

Pilot randomized trial of selective internal radiation therapy vs. chemoembolization in unresectable hepatocellular carcinoma

21 January 2018

1 reference

Y90 Radioembolization Significantly Prolongs Time to Progression Compared With Chemoembolization in Patients With Hepatocellular Carcinoma

21 January 2018

1 reference

Transcatheter Arterial Chemoembolization Plus Radiotherapy Compared With Chemoembolization Alone for Hepatocellular Carcinoma: A Systematic Review and Meta-analysis

21 January 2018

1 reference

Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial

21 January 2018

1 reference

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: subset analyses of the phase III Sorafenib Asia-Pacific trial

21 January 2018

1 reference

Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial

21 January 2018

1 reference

SEARCH: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma.

21 January 2018

1 reference

Comparison of chemoembolization with and without radiation therapy and sorafenib for advanced hepatocellular carcinoma with portal vein tumor thrombosis: a propensity score analysis.

21 January 2018

1 reference

Overall survival in response to sorafenib versus radiotherapy in unresectable hepatocellular carcinoma with major portal vein tumor thrombosis: propensity score analysis

21 January 2018

1 reference

Liver transplantation for small hepatocellular carcinoma: The tumor-node-metastasis classification does not have prognostic power

21 January 2018

1 reference

Small Hypervascular Hepatocellular Carcinoma: Limited Value of Portal and Delayed Phases on Dynamic Magnetic Resonance Imaging

21 January 2018

1 reference

Non-invasive diagnosis of hepatocellular carcinoma ⩽2cm in cirrhosis. Diagnostic accuracy assessing fat, capsule and signal intensity at dynamic MRI

21 January 2018

1 reference

21 January 2018

Screening fundamentals

1 reference

7 January 2021

The Clinical Outcome of Small (<20 mm) Arterially Enhancing Nodules on MRI in the Cirrhotic Liver

1 reference

7 January 2021

Partial hepatectomy vs. transcatheter arterial chemoembolization for resectable multiple hepatocellular carcinoma beyond Milan Criteria: a RCT

1 reference

7 January 2021

Different risk factors and prognosis for early and late intrahepatic recurrence after resection of hepatocellular carcinoma

1 reference

7 January 2021

Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. Hepatoma Prevention Study Group

1 reference

7 January 2021

Liver transplantation for hepatocellular carcinoma

1 reference

7 January 2021

Liver and intestine transplantation in the United States, 1997-2006

1 reference

7 January 2021

Transarterial Chemoembolization Prior to Liver Transplantation in Patients with Hepatocellular Carcinoma

1 reference

7 January 2021

Postoperative transhepatic arterial chemoembolization and portal vein chemotherapy for patients with hepatocellular carcinoma: a randomized study with 131 cases

1 reference

7 January 2021

A randomized trial of hepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma

1 reference

7 January 2021

Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: a multicenter randomized trial. Groupe CHC

1 reference

7 January 2021

A comparative study between sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis

1 reference

7 January 2021